Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.
Also called NCT02354235
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 138 participants
- Sponsor
- Registry
-
NCT02354235
-
- Other papers using this trial's data
- Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02354235. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-01 (actual). Results posted on 2018-08-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Teneligliptin
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct02354235- Content hash
e5fe28073ac486285fb7b5136b21abede22c23dd0a7ff06fbc319d3f5f087580